NCT02791334 2024-09-27
PACT
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
5 trialsNCT00703326 2021-12-06
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Eli Lilly and Company
Phase 3 Completed
NCT01234402 2019-08-14
Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Eli Lilly and Company
Phase 2 Completed
NCT01427933 2017-02-06
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01256567 2014-06-18
A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer
Eli Lilly and Company
Phase 1 Completed